GEN Exclusives

More »

GEN News Highlights

More »
Sep 3, 2009

LEO Pharma to Take Over Peplin for $287.5M

  • LEO Pharma has agreed to acquire Peplin for roughly $287.5 million in cash, or roughly A$342.20. Additionally, LEO will provide Peplin with access to a loan facility to fund ongoing operations until the transaction closes, which is expected to occur by the end of the calendar year.

    The purchase price of $16.99 per common share of Peplin stock, or A$1.03 per Peplin CHESS Depositary Interest, represents a 71.67% premium over the company’s closing price yesterday.

    Most significantly, the Danish firm, which is focused on dermatology and critical care, gains Peplin’s late-stage candidate, PEP005 gel, for actinic keratosis (AK). Peplin plans to complete Phase III development by the end of this year. An NDA filing is expected in mid-2010.

    LEO Pharma discovers, develops, manufactures, and markets drugs globally. It is represented in more than 90 countries and has approximately 3,000 employees, the company points out.

    AK is a precancerous skin lesion, and trials are investigating PEP005 use on both head and nonhead locations. Peplin also has a Phase II study with PEP005 gel in superficial basal cell carcinoma and preliminary data in squamous cell carcinoma and cutaneous warts.

    Ingenol mebutate, or PEP005, is a compound derived from the sap of Euphorbia peplus, a rapidly growing, readily available plant commonly referred to as petty spurge or radium weed. E. peplus has a long history of traditional use for a variety of conditions, according to the companies, including the topical self-treatment of various skin disorders like skin cancer and precancerous skin lesions.

     



Related content

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

Megamerger Dealzapoppin Poll

What company not in this week’s M&A headlines do you think will be at the center of a megamerger, acquisition, or partial selloff this year?